Using epidemiological registry data to provide background rates as context for adverse events in a rheumatoid arthritis drug development program: a coordinated approach-Reference-Cited by-同舟云学术

Using epidemiological registry data to provide background rates as context for adverse events in a rheumatoid arthritis drug development program: a coordinated approach

Published:2015-08-25 Issue:11 Volume:24 Page:1121-1132
ISSN:1053-8569
Container-title:Pharmacoepidemiology and Drug Safety
language:en
Short-container-title:Pharmacoepidemiol Drug Saf

Author:

Nyberg Fredrik¹²,Askling Johan³⁴,Berglind Niklas⁵,Franzén Stefan⁵,Ho Meilien⁶,Holmqvist Marie³,Horne Laura⁷,Lampl Kathy⁸,Michaud Kaleb⁹¹⁰,Pappas Dimitrios A.¹¹,Reed George¹²,Symmons Deborah¹³¹⁴,Tanaka Eiichi¹⁵,Tran Trung N.¹⁶,Verstappen Suzanne M. M.¹⁴,Wesby-van Swaay Eveline¹⁷,Yamanaka Hisashi¹⁵,Greenberg Jeffrey D.¹⁸¹⁹

Affiliation:

1. Medical Evidence & Observational Research Centre, Global Medicines Development; AstraZeneca R&D; Mölndal Sweden

2. Occupational and Environmental Medicine, Sahlgrenska Academy; University of Gothenburg; Gothenburg Sweden

3. Clinical Epidemiology Unit, Department of Medicine Solna; Karolinska Institutet; Stockholm Sweden

4. Department of Rheumatology; Karolinska University Hospital; Stockholm Sweden

5. Biometric & Information Sciences, Global Medicines Development; AstraZeneca R&D; Mölndal Sweden

6. Clinical, Global Medicines Development; AstraZeneca R&D; Macclesfield UK

7. Medical Evidence & Observational Research Centre, Global Medicines Development; AstraZeneca; Wilmington DE USA

8. Clinical, Global Medicines Development; AstraZeneca; Wilmington DE USA

9. University of Nebraska Medical Center; Omaha NE USA

10. National Data Bank for Rheumatic Diseases; Wichita KS USA

11. The College of Physicians and Surgeons; Columbia University Medical Center; New York NY USA

12. University of Massachusetts Medical School; Worcester MA USA

13. NIHR Manchester Musculoskeletal Biomedical Research Unit; Central Manchester NHS Foundation Trust, Manchester Academic Health Science Centre; Manchester UK

14. Arthritis Research UK Centre for Epidemiology; The University of Manchester; Manchester UK

15. Institute of Rheumatology; Tokyo Women's Medical University; Tokyo Japan

16. MedImmune; Gaithersburg MD USA

17. Patient Safety, GRAPSQA, Global Medicines Development; AstraZeneca R&D; Macclesfield UK

18. NYU School of Medicine; New York NY USA

19. Corrona LLC; Southborough MA USA

Funder

AstraZeneca

Arthritis Research UK

AbbVie

Amgen

Janssen